版本:
中国

高管: 石藥集團有限公司 (1093.HK)

1093.HK ( 香港证券交易所 )

13.84HKD
21 May 2019
涨跌 (%)

HK$-0.02 (-0.14%)
收盘
HK$13.86
开盘
HK$13.86
当日最高
HK$13.96
当日最低
HK$13.64
成交量
19,756,431
平均成交量
36,250,512
52 周最高
HK$26.75
52 周最低
HK$9.90

Li, Chunlei 

简历

Mr. Li Chunlei is Executive Director of the Company. Mr. Li is currently the Chief Scientist of the Group in charge of research and development. Mr. Li is also the general manager of a subsidiary of the Company, deputy director of the Novel Pharmaceutical Preparations and Excipients State Key Laboratory and director of the Hebei Pharmaceutical Engineering Technology Centre. Mr. Li holds a bachelor’s degree in engineering (biological pharmaceutics) from Jilin University and Shenyang Pharmaceutical University, a master’s degree in science (microbial and biochemical pharmaceutics) from Jilin University and a doctorate in science (pharmaceutical science) from Shenyang Pharmaceutical University. Mr. Li is mainly engaged in the research, development and commercialisation of nano drugs, and has been responsible for the research and development of approximately 20 nano drugs including “Duomeisu” (doxorubicin hydrochloride liposome injection) and paclitaxel albumin-bound nano particles.

基础薪酬

薪酬, HKD 119,000
限制性股票奖励, HKD --
长期激励计划, HKD --
其他, HKD 3,000
年薪, HKD 122,000

期权薪酬

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
姓名 年薪

Cai Dongchen

13,328,000

Pan Weidong

4,733,000

Chak Kin Man

5,045,000

Li Chunlei

122,000

Lu Hua

4,208,000

Wang Huaiyu

4,205,000
更新时间  2017年 12月 31日 星期日 08:00 BJT